AUS
NZ
UK
CA
USA
IND
Acadia Pharmaceuticals Inc. has announced a significant leadership change with Catherine Owen Adams stepping in as the new Chief Executive Officer (CEO), succeeding Steve Davis. Adams also joins the Acadia Board of Directors, marking a new chapter for the company as it aims to enhance its impact in the pharmaceutical sector.
“We are excited to welcome Catherine Owen Adams as the new CEO of Acadia,” stated Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. He emphasized Adams’s extensive experience and proven track record in the pharmaceutical industry, highlighting her capability to drive growth and innovation. “Her strategic vision and unwavering commitment to improving patient outcomes make her the ideal leader to guide Acadia through its next phase of growth,” Biggar added.
Acadia Pharmaceuticals is approaching $1 billion in sales and boasts a promising pipeline of medicines aimed at treating central nervous system disorders and rare diseases. Biggar expressed confidence that under Adams’s leadership, the company will capitalize on its strengths and continue to enhance its market position.
The Board also recognized the significant contributions of Steve Davis during his tenure as CEO. Dr. Biggar extended heartfelt thanks for Davis’s exceptional leadership, which included the successful approval and commercialization of NUPLAZID, as well as the development and launch of DAYBUE. “Steve’s impact on the biopharmaceutical industry will resonate for years to come,” he noted.
“I am thrilled to join Acadia at such a pivotal and dynamic time for the company,” said Catherine Owen Adams. She expressed her enthusiasm for Acadia’s rich history of innovation and its commitment to improving patient lives, which aligns with her passion for advancing healthcare. Adams is eager to work with the dedicated team at Acadia to drive growth in commercial franchises, accelerate the pipeline, and forge new partnerships.
“I look forward to leading Acadia through its next chapter of innovation and success,” Adams concluded. Her appointment comes at a time when the company is poised to make significant strides in the development of impactful therapies.
The transition to Catherine Owen Adams as CEO marks an exciting moment for Acadia Pharmaceuticals. With her leadership, the company aims to further its mission of transforming healthcare for patients with central nervous system disorders and rare diseases, continuing the legacy of innovation and success established by her predecessor. As Acadia approaches new milestones, stakeholders are eager to see how Adams will navigate this critical phase in the company’s journey.
